Metroplex Clinical Research   Report issue

For profit Phase 1
Founded: Dallas TX United States (1984)

Organization Overview

First Clinical Trial
2016
NCT02828033
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Metroplex Clinical Research Center | Stanley Cohen

Active Ingredients

Drugs in Phase 1 Trials (2)

ac0058ta (1 trial)

rilonacept (arcalyst) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Deafness (Phase 1)

Hearing Loss (Phase 1)

Lupus Erythematosus, Systemic (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 2